SCHEMBL32665623

SCHEMBL32665623

O=C1C=CC(=O)N1CC1CC2(CCN(Cc3ccc(OS(=O)(=O)F)cc3)CC2)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
CYP3A4 P08684 3/20 0.34
CYP2D6 P10635 3/20 0.34
CYP2C9 P11712 2/20 0.34
MMP1 P03956 5/20 0.34
MMP9 P14780 5/20 0.34
MMP13 P45452 5/20 0.34
ADAM17 P78536 5/20 0.34
CCR3 P51677 1/20 0.34
USP2 O75604 3/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPK1 P28482 2/20 0.33
CXCR3 P49682 1/20 0.33
TSHR P16473 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HIF1A Q16665 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32665061 0.88 KCNH2 (0.38) CYP3A4CYP2D6MMP1MMP9MMP13
SCHEMBL32665137 0.85 HRH3 (0.36) CYP3A4CYP2D6CYP2C9MMP1MMP9
SCHEMBL32665550 0.75 MGLL (0.60) GSK3AGSK3BMEN1KMT2AFAAH
SCHEMBL32665508 0.73 CCR8 (0.39) CYP3A4CYP2D6MMP1MMP9MMP13
SCHEMBL32665396 0.71 HRH1 (0.35) CCR3ALDH1A1TSHRSMN1; SMN2KMT2A
SCHEMBL32665432 0.70 NPSR1 (0.36) ALDH1A1MEN1KMT2A
SCHEMBL32665089 0.70 DOCK5 (0.35) ALDH1A1MAPK1CXCR3
SCHEMBL28145882 0.69 SMN1; SMN2 (0.60) ALDH1A1TSHRSMN1; SMN2HIF1AHRH3
SCHEMBL32665268 0.68 CYP2C9 (0.33) CYP3A4CYP2D6CYP2C9MMP9MMP13
SCHEMBL32665642 0.64 ALDH1A1 (0.31) CYP2D6CYP2C9USP2ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD TOPAZ THERAPEUTICS INC (US) 2026-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD RIOX2, ORC3, DCLRE1A GSK3A 4013/4885GSK3B 3967/4885CYP3A4 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.